Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.

@article{Jyonouchi2017PhaseIT,
  title={Phase I trial of low-dose interleukin 2 therapy in patients with Wiskott-Aldrich syndrome.},
  author={S. Jyonouchi and Brenda Gwafila and L. A. Gwalani and Maria Ahmad and Chistopher Moertel and Cecil Holbert and J. Kim and N. Kobrinsky and S. Roy-Ghanta and J. Orange},
  journal={Clinical immunology},
  year={2017},
  volume={179},
  pages={
          47-53
        }
}
  • S. Jyonouchi, Brenda Gwafila, +7 authors J. Orange
  • Published 2017
  • Medicine
  • Clinical immunology
    • BACKGROUND Low dose IL-2 can restore the function of T and NK cells from Wiskott-Aldrich (WAS) patients. However, the safety of in vivo IL-2 in WAS is unknown. OBJECTIVES A phase-I study to assess safety of low dose IL-2 in WAS. METHODS Patients received 5 daily subcutaneous IL-2 injections, every 2months, for three courses. A "3+3" dose escalation method was used. RESULTS 6 patients received the 0.5millionunits/m2/day dose without serious adverse events. However, 2 of 3 patients… CONTINUE READING
    View on PubMed
    doi.org
    15 Citations
    Highly Influential Citations
    1
    Background Citations
    8
    Methods Citations
    1
    Results Citations
    1
    15 Citations
    Citation Type

    Citation Type

    Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD): a phase 2, multicentre, double-blind, randomized, placebo-controlled trial
    • 3
    Low-dose interleukin-2 alleviates dextran sodium sulfate-induced colitis in mice by recovering intestinal integrity and inhibiting AKT-dependent pathways
    • 6
    • Highly Influenced
    • PDF
    HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice
    Low Dose Medicine: theoretical background and scientific evidence
    • 2
    Clinical Manifestations and Pathophysiological Mechanisms of the Wiskott-Aldrich Syndrome
    • 58
    Wiskott-Aldrich syndrome in four male siblings from a consanguineous family from Lebanon.
    Primary Immunodeficiency Diseases: Current and Emerging Therapeutics
    • 24
    • PDF
    Immune responses against tumors controlled by the actin cytoskeleton : lessons from primary immunodeficiencies
    Higher Incidence of B Cell Malignancies in Primary Immunodeficiencies: A Combination of Intrinsic Genomic Instability and Exocytosis Defects at the Immunological Synapse
    • PDF
    Monogenic Immune Diseases Provide Insights Into the Mechanisms and Treatment of Chronic Graft-Versus-Host Disease

    References

    SHOWING 1-10 OF 28 REFERENCES
    Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata.
    • 138
    • PDF
    Thrombocytopenia during immunotherapy with interleukin-2 by constant infusion.
    • 42
    Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis.
    • 564
    Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial.
    • 235
    Interleukin-2 and regulatory T cells in graft-versus-host disease.
    • 794
    • PDF
    An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome.
    • 52
    Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
    • 63
    • PDF
    X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options.
    • 147
    Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
    • 170
    Hematopoietic Stem Cell Transplantation for X-Linked Thrombocytopenia With Mutations in the WAS gene
    • 16